{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["31(4)"],"submitter":["Ludwig H"],"journal":["Leukemia"],"pagination":["997-1000"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC5383929"],"repository":["biostudies-literature"],"pubmed_title":["Olaptesed pegol, an anti-CXCL12/SDF-1 Spiegelmer, alone and with bortezomib-dexamethasone in relapsed/refractory multiple myeloma: a Phase IIa Study."],"pmcid":["PMC5383929"],"pubmed_authors":["Leitgeb C","Vauleon S","Dummler T","Foa R","Engelhardt M","Petrucci MT","Garderet L","Weisel K","Beyer D","Greil R","Baumann M","Leleu X","Cafro AM","Ludwig H","Riecke K","Yakoub-Agha I","Zboralski D","Kruschinski A"],"additional_accession":[]},"is_claimable":false,"name":"Olaptesed pegol, an anti-CXCL12/SDF-1 Spiegelmer, alone and with bortezomib-dexamethasone in relapsed/refractory multiple myeloma: a Phase IIa Study.","description":null,"dates":{"release":"2017-01-01T00:00:00Z","publication":"2017 Apr","modification":"2026-05-05T15:23:31.55Z","creation":"2026-04-07T21:48:14.643Z"},"accession":"S-EPMC5383929","cross_references":{"pubmed":["28074071"],"doi":["10.1038/leu.2017.5"]}}